#KRAS

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Researchers have programmed bacteria to become "biosensors," seeking out and capturing tumor DNA with mutations in the KRAS gene.

Can Bacteria Help Find Cancer?

A study in mice found that engineered "bacterial biosensors” could detect DNA shed by colorectal cancer tumors.

Studying the Role of Sox9 in Lung Cancer

A University of Colorado cancer researcher shows that overexpression of transcription factor Sox9 results in resistance to immunotherapy.

Barb Spanjer has been free of pancreatic cancer since 2020.

Individualized Care Provides Hope for Patient With Stage 4 Pancreatic Cancer

Barb Spanjer worked with a University of Colorado Cancer Center multidisciplinary team on a personalized, multi-front treatment plan.

In Mouse Study, KRAS-Targeted Drug Shows Potential Against Pancreatic Cancer

KRAS has been one of the most hard-to-hit targets in cancer research.

Iron-willed: How Pancreatic Cancers Resist Targeted Therapy

A potential pancreatic cancer treatment might not only inhibit the KRAS-MAPK pathway but also disrupt a breakdown of iron, research shows.

FDA Approves Second KRAS Drug for Lung Cancer

Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.

Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?

The new approach takes advantage of the natural process by which cells break down proteins into fragments called peptides.

Drug Turns Cancer Gene Into an “Eat Me” Flag for the Immune System

Promising research shows that marking the mutated KRAS protein of cancer cells can signal the immune system to destroy that cancer.

Experimental KRAS Inhibitor Shrinks Lung Tumors

The median progression- free survival time was 6.5 months, and the median overall survival time was 12.6 months.

Targeted Drug Achieves 43% Response Rate in KRAS-Mutated Lung Cancer

Experimental KRAS inhibitor adagrasib also shows activity against lung cancer that has spread to the brain.

A new KRAS drug binds to a hidden pocket in the mutant protein, inactivating it.

KRAS Inhibitor May Offer Long-Term Benefit for Lung Cancer Patients

Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.

Top 10 Cancer Science Highlights of 2021

A look back at some of the most important science and treatment news Cancer Health covered this year.

Leading Efforts Against KRAS, the “Undruggable” Cancer Target

Damon Runyon Cancer Research Foundation scientists work to develop drugs for people with KRAS-driven cancers.

Most Lung Cancer Patients Who Never Smoked Have Targetable Mutations

Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.

First KRAS Drug Now Available

Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.

First KRAS-Blocking Drug Approved for Advanced Lung Cancer

Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.

#KRAS

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Experimental Pan-KRAS Inhibitor Enters Clinical Trials

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

New Approach Attacks ’Undruggable’ Cancers From the Outside In

Can Bacteria Help Find Cancer?

Studying the Role of Sox9 in Lung Cancer

Individualized Care Provides Hope for Patient With Stage 4 Pancreatic Cancer

In Mouse Study, KRAS-Targeted Drug Shows Potential Against Pancreatic Cancer

Iron-willed: How Pancreatic Cancers Resist Targeted Therapy

FDA Approves Second KRAS Drug for Lung Cancer

Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?

Drug Turns Cancer Gene Into an “Eat Me” Flag for the Immune System

Experimental KRAS Inhibitor Shrinks Lung Tumors

Targeted Drug Achieves 43% Response Rate in KRAS-Mutated Lung Cancer

KRAS Inhibitor May Offer Long-Term Benefit for Lung Cancer Patients

Top 10 Cancer Science Highlights of 2021

Leading Efforts Against KRAS, the “Undruggable” Cancer Target

Most Lung Cancer Patients Who Never Smoked Have Targetable Mutations

First KRAS Drug Now Available

First KRAS-Blocking Drug Approved for Advanced Lung Cancer

Science News

Blog: Food and Drug Administration (FDA)